Liver/Kidney Microsome Type 1 Antibodies
Liver/Kidney microsomal type 1 (LKM-1) antibodies are specific autoantibodies serving as diagnostic markers for autoimmune hepatitis (AIH) type 2, a chronic liver condition characterized by autoimmune destruction of hepatocytes following a breakdown in immune tolerance. AIH has an estimated prevalence of approximately 18 cases per 100,000 individuals, occurring at any age but with a higher incidence among females, with a male-to-female ratio ranging from 1:3 to 1:9.
Symptom onset can occur at any age, although it is most commonly diagnosed during the fourth or fifth decades of life. Clinical manifestations are typically nonspecific, including fatigue, jaundice, abdominal pain, and arthralgias. Laboratory tests frequently reveal elevated liver enzymes, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT). Alkaline phosphatase (ALP) levels usually remain within normal limits. Elevated total serum IgG levels are common, reflecting immune activation. AIH is classified into two primary types based on autoantibody profiles:
- AIH Type 1: Associated with anti-smooth muscle antibodies (SMA, specifically against F-actin) and antinuclear antibodies (ANA).
- AIH Type 2: Associated with Liver/Kidney Microsomal Type 1 (LKM-1) antibodies.
LKM-1 antibodies predominantly target the enzyme cytochrome P450 2D6 (CYP2D6), found in the microsomes of hepatocytes and proximal renal tubular cells. Detection of these antibodies is typically achieved by enzyme-linked immunosorbent assay (ELISA) or indirect immunofluorescence, which characteristically demonstrates staining in the hepatocyte cytoplasm and renal proximal tubular cells.
- Differential diagnosis of autoimmune hepatitis type 2 from other forms of hepatitis
- Monitoring disease progression and assessing therapeutic response in autoimmune hepatitis
Negative: ≤ 20.0 U (No clinically significant LKM-1 antibodies detected; autoimmune hepatitis type 2 is unlikely).
Equivocal: 20.1 – 24.9 U (Borderline results; recommend clinical correlation and retesting after a suitable interval).
Positive: ≥ 25.0 U (Consistent with autoimmune hepatitis type 2; clinical correlation with biochemical, histological, and radiological findings recommended).
Negative (< or = 20.0 U)
Serum (SST tube).
Stability
- Ambient: 3-5 days.
- Refrigerated: 7 days
- Frozen: 21 days
- Pract Lab Med. 2023 Jan 7;33:e00307. [PMID: 36660178]
- Hepatology. 2010 Jun;51(6):2193-213. [PMID: 20513004]
- J Clin Pathol. 2002 Dec;55(12):906-9. [PMID: 12461054]
- J Immunol Methods. 1999 Mar 4;223(2):227-35. [PMID: 10089101]
- J Autoimmun. 2013 Oct;46:17-24. [PMID: 24016388]